Aims Randomized controlled trials have shown that cardiac resynchronization therapy (CRT) prolongs survival in patients with heart failure. No studies have explored survival after CRT in relation to individuals in the general population (relative survival, RS). We sought to determine observed and RS after CRT in a nationwide cohort undergoing CRT. Methods and results A national administrative database was used to quantify observed mortality for patients undergoing CRT. Relative survival (RS) was quantified using life tables. In 50 084 patients [age 72.1 ± 11.6 years (mean ± standard deviation)] undergoing CRT with (CRT-D) (n = 25 273) or without (CRT-P) defibrillation (n = 24 811) over 8.8 years (median follow-up 2.7 years, interquartile ra...
Aims Treatment decisions in patients with scimitar syndrome (SS) are often challenging, especiall...
Aims We hypothesized that a decline in admissions with heart failure during COVID-19 pandemic would...
AIMS: To investigate the effect of high-dose iron vs. low-dose intravenous (IV) iron on myocardial i...
Aims Randomized controlled trials have shown that cardiac resynchronization therapy (CRT) prolongs s...
Aims: Left atrial (LA) function is a marker of prognosis in patients with heart failure. The prognos...
Aims: Cardiac resynchronization therapy defibrillators (CRT-D) are able to monitor various parameter...
AIMS: To investigate European guideline treatment target achievement in cardiovascular risk factors,...
Aim We tested the hypothesis that metformin may regress left ventricular hypertrophy (LVH) in pat...
Aims: Cardiac resynchronization therapy (CRT) upgrades may be less likely to improve following inter...
Aims The optimal method of revascularization for patients with left main coronary artery disease (L...
Aims Current evidence on dyslipidaemia management has expanded to novel treatments and very low a...
Aims To investigate European guideline treatment target achievement in cardiovascular risk factors, ...
Aims: Heart failure may occur following acute myocardial infarction, but with the use of high-sens...
Aims: Risk estimation is important to motivate patients to adhere to treatment and to identify th...
AIMS: We aimed to determine the sex differences in longitudinal systolic and diastolic blood pressur...
Aims Treatment decisions in patients with scimitar syndrome (SS) are often challenging, especiall...
Aims We hypothesized that a decline in admissions with heart failure during COVID-19 pandemic would...
AIMS: To investigate the effect of high-dose iron vs. low-dose intravenous (IV) iron on myocardial i...
Aims Randomized controlled trials have shown that cardiac resynchronization therapy (CRT) prolongs s...
Aims: Left atrial (LA) function is a marker of prognosis in patients with heart failure. The prognos...
Aims: Cardiac resynchronization therapy defibrillators (CRT-D) are able to monitor various parameter...
AIMS: To investigate European guideline treatment target achievement in cardiovascular risk factors,...
Aim We tested the hypothesis that metformin may regress left ventricular hypertrophy (LVH) in pat...
Aims: Cardiac resynchronization therapy (CRT) upgrades may be less likely to improve following inter...
Aims The optimal method of revascularization for patients with left main coronary artery disease (L...
Aims Current evidence on dyslipidaemia management has expanded to novel treatments and very low a...
Aims To investigate European guideline treatment target achievement in cardiovascular risk factors, ...
Aims: Heart failure may occur following acute myocardial infarction, but with the use of high-sens...
Aims: Risk estimation is important to motivate patients to adhere to treatment and to identify th...
AIMS: We aimed to determine the sex differences in longitudinal systolic and diastolic blood pressur...
Aims Treatment decisions in patients with scimitar syndrome (SS) are often challenging, especiall...
Aims We hypothesized that a decline in admissions with heart failure during COVID-19 pandemic would...
AIMS: To investigate the effect of high-dose iron vs. low-dose intravenous (IV) iron on myocardial i...